{"prompt": "['10 REFERENCES', '1. Estey E. Reducing mortality associated with immediate treatment complications of adult', 'leukemias. Semin Hematol. 2001; 38:32-37.', '2. Appelbaum FR et al. Age and acute myeloid leukemia. Blood. 2006; 107:3481-3485.', '3. Vaughn JE et al. Resource Utilization and Safety of Outpatient Management Following Intensive', 'Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome:', 'A Nonrandomized Clinical Comparative Analysis. JAMA Oncol. 2015; 1(8): 1120-1127.', '4. Halim TY et al. Positive impact of selective outpatient management of high-risk acute', 'myelogenous leukemia on the incidence of septicemia. Ann Oncol. 2007 Jul;18(7):1246-52.', '5. Getz KD et al. A comparison of resource utilization following chemotherapy for acute myeloid', 'leukemia in children discharged versus children that remain hospitalized during neutropenia.', 'Cancer Med. 2015;4(9):1356-64', '6.', 'M\u00f8ller T et al. Safe and feasible outpatient treatment following induction and consolidation', 'chemotherapy for patients with acute leukaemia. Eur J Haematol. 2010 Apr;84(4):316-22.', '7. Khouri J, Majhail NS. Advances in delivery of ambulatory autologous stem cell transplantation', 'for multiple myeloma. Curr Opin Support Palliat Care. 2017 Dec; 11(4):361-5.', '8. Martino M et al. A Comparative Assessment of Quality of Life in Patients with Multiple', 'Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and', 'Inpatient Model. Biol Blood Marrow Transplant. 2018;24(3):608-613', '9. Othus M et al. Declining Rates of Treatment-Related Mortality in Patients with Newly-diagnosed', 'AML Given \"Intense\" Induction Regimens: A Report from SWOG and MD Anderson.', 'Leukemia. 2014 Feb; 28(2): 289-292.', '10. Percival ME, Tao L, Medeiros BC, Clarke CA. Improvements in the early death rate among 9380', 'patients with acute myeloid leukemia after initial therapy: a SEER database', 'analysis. Cancer. 2015; 121:2004-2012.', '11. Vaughn JE, Buckley SA, Walter RB. Outpatient care of patients with acute myeloid leukemia:', 'Benefits, barriers, and future considerations. Leuk Res. 2016; 45: 53-58.', '12. Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL. Economic burden of acute', 'myeloid leukemia: a literature review. Cancer Treat Rev. 2004; 30:237-247.', '13. Nerich V et al. Induction-related cost of patients with acute myeloid leukemia in France. Int J', 'Clin Pharm. 2011; 33:191-199. -', '14. Leunis A, Blommestein HM, Huijgens PC, Blijlevens NM, Jongen-Lavrencic M, Uyl-de Groot', 'CA. The costs of initial treatment for patients with acute myeloid leukemia in the', 'Netherlands. Leuk Res. 2013; 37:245-250.', 'MCW Protocol No:IIT-Michaelis-OutpatientCPX-351', 'p63', 'Version No.: 3', 'Version Date: 04/15/2020']['15. Irish WD, Ryan M, Gache L, Gunnarsson C, Bell T, Shapiro M. Acute myeloid leukemia (AML):', 'a retrospective claims analysis of resource utilization and expenditures [abstract] Blood. 2015;', '126:5633.', '16. Walter RB, Lee SJ, Gardner KM, Chai X, Shannon-Dorcy K, Appelbaum FR, Estey EH..', 'Outpatient management following intensive induction chemotherapy for myelodysplastic', 'syndromes and acute myeloid leukemia: a pilot study. Haematologica. 2011; 96(6):914-917.', '17. Walter RB, Taylor LR, Gardner KM, Dorcy KS, Vaughn JE, Estey EH. Outpatient management', 'following intensive induction or salvage chemotherapy for acute myeloid leukemia. Clin Adv', 'Hematol Oncol. 2013;11(9):571-577.', '18. Vaughn JE et al. Resource Utilization and Safety of Outpatient Management Following Intensive', 'Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome:', 'A Nonrandomized Clinical Comparative Analysis. JAMA Oncol. 2015; 1(8): 1120-7.', '19. Lancet JE et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, VS', 'cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014; 123(21): 3239-3246', '20. Lancet JE et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus', 'Conventional Cytarabine Plus Daunorubicin in Older Patients with Newly Diagnosed Secondary', 'Acute Myeloid Leukemia. J Clin Oncol. 2018 Sep 10;36(26):2684-2692', '21. Kolitz JE et al. Efficacy by consolidation administration site: Subgroup analysis of a phase III study', 'of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia', '(AML). Journal of Clinical Oncology 2017 5:15_suppl, 7036-7036', '22. Williams MS, Snyder DC, Sloane R, Levens J, Flynn KE, Dombeck CB, et al. A comparison of', 'cancer survivors from the PROMIS study selecting telephone versus online questionnaires.', 'Psychooncology. 2013;22(11):2632-5', '23. Bjorner JB, Rose M, Gandek B, Stone AA, Junghaenel DU, Ware JE, Jr. Method of', 'administration of PROMIS scales did not significantly impact score level, reliability, or validity.', 'Journal of clinical epidemiology. 2014;67(1):108-13.', '24.', \"Bridges JF, Oakes AH, Reinhart CA, Voyard E, O'Donoghue B. Developing and piloting an\", 'instrument to prioritize the worries of patients with acute myeloid leukemia. Subject Prefer', 'Adherence. 2018 Apr 27; 12:647-655.', 'MCW Protocol No: IIT-Michaelis-OutpatientCPX-351', 'p64', 'Version No.: 3', 'Version Date: 04/15/2020']\n\n###\n\n", "completion": "END"}